De-Sone LA injection and Polivy
Determining the interaction of De-Sone LA injection and Polivy and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with inducers of CYP450 3A4 may decrease exposure to unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of polatuzumab vedotin. MMAE is a substrate for CYP450 3A4. Concomitant use of polatuzumab vedotin with rifampin, a potent CYP450 3A4 inducer, is predicted to decrease unconjugated MMAE exposure (AUC) by 63% according to the product labeling. No data are available for other, less potent CYP450 3A4 inducers. MANAGEMENT: The potential for diminished pharmacologic effects of polatuzumab vedotin should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected. References "Product Information. Polivy (polatuzumab vedotin)." Genentech, South San Francisco, CA.
Professional:MONITOR: Coadministration with inducers of CYP450 3A4 may decrease exposure to unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of polatuzumab vedotin. MMAE is a substrate for CYP450 3A4. Concomitant use of polatuzumab vedotin with rifampin, a potent CYP450 3A4 inducer, is predicted to decrease unconjugated MMAE exposure (AUC) by 63% according to the product labeling. No data are available for other, less potent CYP450 3A4 inducers.
MANAGEMENT: The potential for diminished pharmacologic effects of polatuzumab vedotin should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.
- "Product Information. Polivy (polatuzumab vedotin)." Genentech, South San Francisco, CA.
Generic Name: dexamethasone
Brand name: De-Sone LA, Dexacen-4, Dexasone, Dexasone LA, Solurex, Solurex LA, Baycadron, Dexamethasone Intensol, DexPak 10 Day Taperpak, DexPak 13 DayTaperpak, DexPak 6 DayTaperpak, Decadron, DexPak, TaperDex, Zema-Pak, ZoDex, Zonacort
Synonyms: De-Sone LA (injection)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- De-Sone LA injection-Polmon
- De-Sone LA injection-Polocaine
- De-Sone LA injection-Polocaine Dental (Mepivacaine and Levonordefrin)
- De-Sone LA injection-Polocaine Dental (Mepivacaine)
- De-Sone LA injection-Polocaine Injection
- De-Sone LA injection-Polocaine-MPF
- Polivy-Deblitane
- Polivy-Decadron
- Polivy-Decadron Elixir
- Polivy-Decara
- Polivy-Decavac
- Polivy-Decavac (Td) Td